Completed PHASE3 INTERVENTIONAL 1-arm NCT00566631

An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia (PERTAIN)

Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia

Sponsor: Janssen-Cilag International NV

Conditions Schizophrenia

Interventions Paliperidone

Updated 7 times since 2017 Last updated: Jun 27, 2013 Started: Jul 31, 2007 Primary completion: May 31, 2008 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Schizophrenia and is currently completed. Janssen-Cilag International NV leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag International NV

Data source: Janssen-Cilag International NV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augsburg, Germany , Be-Er Ya-Acov, Israel , Beersheba, Israel , Bonn, Germany , Bucharest, Romania , Cluj-Napoca, Romania , Craiova, Romania , Dieppe, France , Gda Sk Poland, Poland , Gmina Świecie, Poland and 20 more locations